Corbenic Partners’s Bristol-Myers Squibb BMY Stock Holding History

Corbenic Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-101	Closed	-$7K	–	277
2021 Q2	$7K	Buy	101 +20	+25%	+$1.3K	﹤0.01%	194
2021 Q1	$5K	Buy	+81	New	+$5.04K	﹤0.01%	201
2020 Q2	–	Sell	-50	Closed	-$3K	–	163
2020 Q1	$3K	Hold	50	–	–	﹤0.01%	136
2019 Q4	$3K	Buy	+50	New	+$2.86K	﹤0.01%	146
2017 Q4	$49K	Hold	800	–	–	0.06%	63
2017 Q3	$51K	Hold	800	–	–	0.07%	66
2017 Q2	$45K	Hold	800	–	–	0.06%	68
2017 Q1	$44K	Sell	800 -306	-28%	-$16.8K	0.05%	73
2016 Q4	$65K	Hold	1,106	–	–	0.07%	60
2016 Q3	$60K	Buy	1,106 +306	+38%	+$19.7K	0.06%	65
2016 Q2	$59K	Hold	800	–	–	0.06%	61
2016 Q1	$51K	Sell	800 -104	-12%	-$6.56K	0.05%	62
2015 Q4	$62K	Buy	904 +104	+13%	+$6.87K	0.06%	51
2015 Q3	$47K	Buy	+800	New	+$50.8K	0.04%	60

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Corbenic Partners's BMY Position: Q3 2021 in Review

Corbenic Partners sold out of Bristol-Myers Squibb (BMY) in Q3 2021, closing a stake of 101 shares — an estimated $7K sold.

Corbenic Partners first reported a position in BMY in Q3 2015 and held it in 14 quarters. The position peaked at $65K in Q4 2016. 2,293 funds tracked by Wall St. Rank hold BMY as of Q3 2021.

Corbenic Partners reported no remaining Bristol-Myers Squibb position as of Q3 2021 after selling out during the quarter.
Corbenic Partners sold 101 Bristol-Myers Squibb shares in Q3 2021, an estimated $7K.
Corbenic Partners first reported a position in Bristol-Myers Squibb in Q3 2015 and held it in 14 quarters.
Corbenic Partners's Bristol-Myers Squibb position peaked at $65K in Q4 2016.
2,293 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2021.

Based on Corbenic Partners's 13F filing for Q3 2021, filed 13 Oct 2021.